U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT07454187) titled 'To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma' on Feb. 25.
Brief Summary: The primary objective of this study was to evaluate the safety and tolerability of SG2918 in patients with relapsed/refractory multiple myeloma.
Study Start Date: March 14
Study Type: INTERVENTIONAL
Condition:
Relapsed/Refractory Multiple Myeloma
Intervention:
DRUG: SG2918
The study adopts a "3+3" dosing escalation approach. Initially, three dose groups are set, namely 1.5mg/kg, 1.8mg/kg, and 2mg/kg. The SG2918 will be administrated by intravenous infusion every 3 weeks.
Recruitment Status: NOT_YET_RECRUITING
S...